Last updated: February 19, 2026
Darunavir is an antiretroviral medication used primarily to treat HIV-1 infection. It belongs to the protease inhibitor class and is marketed under various brand names, including Prezista. Multiple suppliers and manufacturers globally produce darunavir, often through licensing agreements with patent holders.
Major Suppliers and Manufacturers
| Company |
Country |
Manufacturing Capacity |
Market Presence |
Notable Licensing/Partnerships |
| Janssen Pharmaceuticals (Johnson & Johnson) |
USA |
Large-scale production |
Global |
Original patent holder, exclusive rights for primary formulations |
| Mylan |
Netherlands / India |
Variable, large scale |
Global |
Manufactures generic formulations under license |
| Cipla |
India |
Moderate to large |
Africa, Asia, Latin America |
Produces generic versions, often at lower costs |
| Sun Pharmaceutical Industries |
India |
Large-scale |
Asia, Middle East, Latin America |
Markets generic versions |
| Cadila Healthcare |
India |
Moderate |
Asia, Africa |
Distributes generic formulations |
| Aurobindo Pharma |
India |
Large-scale |
India, US, Europe |
Manufactures generic formulations |
Production and Licensing Dynamics
- Patent Status: Originally patented by Janssen (a Johnson & Johnson subsidiary) until 2014 globally, with some jurisdictions extending patent rights through secondary patents. Generic manufacturers gained entry after patent expiration.
- Generics: The expiration of key patents in 2014 in the US and Europe led to a proliferation of generic darunavir products.
- Bioequivalence and Quality: Regulatory bodies such as the US FDA and EMA approve generic manufacturers that demonstrate bioequivalence and manufacturing standards.
Regulatory and Supply Chain Notes
- WHO Essential Medicines List: Darunavir is included for patients who have failed other therapies, which influences manufacturing demand.
- Supply Chain Considerations: Capacity constraints have not been significant post-2014, but geopolitical and trade policies can affect distribution, especially for generic producers in India and China.
- Distribution Channels: Manufacturers sell directly to regional distributors, government procurement agencies, and international health organizations.
Market Share and Competition
| Company |
Estimated Market Share (2022) |
Key Markets |
| Johnson & Johnson (Janssen) |
50% |
North America, Europe, select Asian markets |
| Mylan |
15% |
Africa, Latin America, parts of Asia |
| Cipla |
10% |
Africa, India, Southeast Asia |
| Other Generics |
25% |
Various emerging markets |
Market competition has intensified with multiple generic manufacturers, leading to reduced costs and expanded access in low- and middle-income economies.
Key Supply Sources Summary
- Original Manufacturer: Janssen (Johnson & Johnson) controls patents and primary supply.
- Generics: Multiple global manufacturers produce licensed and unlicensed formulations mainly from India, China, and Europe.
- Future Trends: Biosimilar or long-acting formulations may impact supply chains; manufacturing capacity expansions continue in India and China.
Citations
- WHO. (2022). List of Essential Medicines. World Health Organization. https://www.who.int/publications/i/item/9789240039374
- US Food and Drug Administration (FDA). (2014). Drug Approvals and Manufacturing Approvals. https://www.fda.gov/drugs/approved-drugs
- European Medicines Agency (EMA). (2022). Summary of Product Characteristics for Prezista. https://www.ema.europa.eu/en/documents/product-information/prezista-epar-case-approval_en.pdf
- IMS Health. (2022). Global HIV Portfolio and Supply Data. IQVIA. https://www.iqvia.com
- Kaiser Family Foundation. (2021). HIV/AIDS Treatment Market and Access. https://www.kff.org
Key Takeaways
- Multiple manufacturers produce darunavir, with Janssen holding original patents and most licensing rights for branded formulations.
- The global generic market expanded significantly after patent expiration in 2014, led by Indian manufacturers like Mylan, Cipla, and Aurobindo.
- Supply chains are robust but subject to geopolitical, economic, and regulatory shifts.
- Market share favors Janssen for branded drugs; generics dominate access in lower-income regions.
- Future manufacturing trends include biosimilars and long-acting formulations, influencing supply stability.
FAQs
Q1: When did the patent for darunavir expire in major markets?
A1: The primary patents expired in 2014 in the US, Europe, and other jurisdictions, allowing generic manufacturers to enter.
Q2: Who are the leading generic suppliers of darunavir?
A2: Mylan, Cipla, and Aurobindo are among the top generic producers, primarily based in India.
Q3: Does Janssen still control the global supply?
A3: Janssen owns the original patent and manufacturing rights for branded formulations; however, generics are widely produced by other firms post-patent expiry.
Q4: Are there any recent developments affecting darunavir supply?
A4: Expanding manufacturing capacity and new formulations are ongoing. Regulatory approvals for biosimilars or long-acting injectables may impact future supply.
Q5: Which regions are most dependent on generic darunavir?
A5: Africa, South America, and parts of Asia rely heavily on generic formulations to access treatment.
[1] World Health Organization. (2022). List of Essential Medicines.
[2] US Food and Drug Administration. (2014). Drug Approvals.
[3] European Medicines Agency. (2022). Prezista SPC.
[4] IQVIA. (2022). Global HIV Portfolio.
[5] Kaiser Family Foundation. (2021). HIV/AIDS Treatment Market.
